Phenatic Acids A and B, New Potentiators of Antifungal Miconazole Activity Produced by Streptomyces sp. K03-0132

Abstract

Two new phenols, designated phenatic acids A and B, were isolated along with known actiphenol, from the culture of Streptomyces sp. K03-0132 by solvent extraction, silica gel column chromatography and HPLC. Their structures were elucidated by spectroscopic analyses including mainly various NMR experiments. They have a common 1-hydroxy 2, 4-dimethyl benzene ring. These compounds potentiate miconazole activity against Candida albicans. Phenatic acid B also showed moderate antimicrobial activity against Bacillus subtilis, Staphylococcus aureus, Bacteroides fragilis and Acholeplasma laidlawii.

Nosokomycins, new antibiotics discovered in an in vivo-mimic infection model using silkworm larvae. II: Structure elucidation

“…[1][2][3] In the course of in vivo-mimic screening using silkworm larvae to discovery antibiotics that are active against methicillin-resistant Staphylococcus aureus, nosokomycins A, B, C and D ( Figure 1) were isolated as active components from the culture broth of Streptomyces sp. K04-0144.…”

Trichocyalides A and B, new inhibitors of alkaline phosphatase activity in bone morphogenetic protein-stimulated myoblasts, produced by Trichoderma sp. FKI-5513

“…Antimicrobial activity against 14 species of microorganisms was measured by our established method 21 using Bacillus subtilis PCI 219, Staphylococcus aureus FDA 209P, Kocuria rhizophila ATCC 9341, Mycobacterium smegmatis ATCC 607, Escherichia coli NIHJ, Pseudomonas aeruginosa P-3, Xanthomonas campestris pv. Oryzae KB 88, Bacteroides fragilis ATCC 23745, Acholeplasma laidlawii PG 8, Pyricularia oryzae KF 180, Aspergillus niger ATCC 6275, Mucor racemosus IFO 4581, Candida albicans ATCC 64548 and Saccharomyces cerevisiae.…”

Tensidols, New Potentiators of Antifungal Miconazole Activity, Produced by Aspergillus niger FKI-2342

“…Antimicrobial activity against 14 species of microorganisms was measured by our established method [4] The following media were employed: GAM agar (Nissui Seiyaku Co., Tokyo, Japan) for Bacteroides fragilis; Bacto PPLO agar (Sanko Junyaku Co. Ltd., Tokyo, Japan) supplemented with 15% horse serum, 0.1% glucose, 0.25% phenol red (5 mg/ml) and 1.5% agar for A. laidlawii; Taiyo agar (Shimizu Syokuhin Kaisya Ltd., Shizuoka, Japan) for the other bacteria; a medium composed of 1.0% glucose, 0.5% yeast extract and 0.8% agar for fungi and yeasts. A paper disk (i.d.…”

“…patients receiving organ transplants and cancer chemotherapy, or those infected by human immunodeficiency virus, are particularly prone to such infections [1]. We reported actofunicone [2], beauvericins [3], phenatic acids [4] and citridones [5], produced by fungal or actinomycete strains, as potentiators of miconazole activity against C. albicans. During the course of our screening program, new compounds, designated tensidols A and B ( Fig.…”